Literature DB >> 23695158

[Management of prostate cancer in the elderly].

G Hatiboglu1, B Hadaschik, D Teber, S Duensing, M Hohenfellner, S Pahernik.   

Abstract

The management of prostate cancer in elderly patients is a topic of controversial discussion. The current guidelines recommend diagnosis and treatment of prostate cancer only in patients with a life expectancy of more than 10 years. Especially in elderly patients pre-existing comorbidities play a crucial role in life expectancy. In clinical practice mostly patient age alone is considered for the treatment decision; however, a guideline-based therapy of prostate cancer should also be offered to elderly patients. The treatment decision should be based on patient general health status and the oncological risk. The patient individual health status can be determined on the basis of comorbidities present and patient nutritional and performance status. For an optimal therapy regime the oncological risk has to be considered in treatment decisions. The aim of this article is to give an overview of risk stratification and treatment options for localized and metastatic prostate cancer in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695158     DOI: 10.1007/s00120-013-3152-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  32 in total

1.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

2.  Variations in morbidity after radical prostatectomy.

Authors:  Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

Review 3.  Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.

Authors:  Jean-Pierre Droz; Lodovico Balducci; Michel Bolla; Mark Emberton; John M Fitzpatrick; Steven Joniau; Michael W Kattan; Silvio Monfardini; Judd W Moul; Arash Naeim; Hendrik van Poppel; Fred Saad; Cora N Sternberg
Journal:  Crit Rev Oncol Hematol       Date:  2010-01       Impact factor: 6.312

4.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Prostate cancer in the elderly.

Authors:  Hans Heinzer; Thomas Steuber
Journal:  Urol Oncol       Date:  2009 Nov-Dec       Impact factor: 3.498

Review 6.  Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity.

Authors:  Karen E Hoffman
Journal:  Semin Radiat Oncol       Date:  2012-10       Impact factor: 5.934

Review 7.  Management of metastatic prostate cancer: the crucial role of geriatric assessment.

Authors:  Jean-Pierre Droz; Agnieska Chaladaj
Journal:  BJU Int       Date:  2008-03       Impact factor: 5.588

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

9.  Continued undertreatment of older men with localized prostate cancer.

Authors:  Kevin L Schwartz; Shabbir M H Alibhai; George Tomlinson; Gary Naglie; Murray D Krahn
Journal:  Urology       Date:  2003-11       Impact factor: 2.649

10.  Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram.

Authors:  Lee Richstone; Fernando J Bianco; Hiral H Shah; Michael W Kattan; James A Eastham; Peter T Scardino; Douglas S Scherr
Journal:  BJU Int       Date:  2008-03       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.